Advertisement

Topics

Summit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDI

07:16 EDT 11 Sep 2017 | FinanzNachrichten

Summit Therapeutics plc ('Summit Therapeutics', Summit', or the 'Company')SUMMIT AWARDED BARDA CONTRACT WORTH UP TO $62 MILLION TO SUPPORT THE DEVELOPMENT OF RIDINILAZOLE FOR THE TREATMENT OF C. D...

Original Article: Summit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDI

NEXT ARTICLE

More From BioPortfolio on "Summit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDI"

Quick Search
Advertisement